We aimed to investigate cardiovascular outcomes of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus after myocardial infarction in a Swedish nationwide registry. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.